Literature DB >> 11424139

Characterization of a long-term survivor with Stüve-Wiedemann syndrome and mosaicism of a supernumerary marker chromosome.

E Chen1, P D Cotter, R A Cohen, R S Lachman.   

Abstract

Stüve-Wiedemann syndrome (SWS) is typically lethal in the neonatal period; only two patients have been reported with a longer survival. We report a new patient with SWS, who at 9 years of age is one of the longest survivors with this disorder. In addition to the characteristic features of SWS, she has a number of unique clinical signs, including lack of corneal and patellar reflexes, a smooth tongue with no fungiform papillae, chronic gingival abscesses, mottled, poor dentition, blotchy pigmentation of the skin, unusual infections, multiple fractures, and progressive scoliosis. Cytogenetic analysis identified mosaicism for a supernumerary marker chromosome (SMC), seen in the majority of amniocytes, blood, and skin fibroblasts. The SMC was shown to be derived from chromosome 5 and contains euchromatin. The significance of the SMC to the etiology of SWS is unknown. This patient further demonstrates that SWS is not universally lethal. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11424139     DOI: 10.1002/ajmg.1382

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

1.  Craniocervical CT and MR imaging of Schwartz-Jampel syndrome.

Authors:  Sarah S Samimi; Walter S Lesley
Journal:  AJNR Am J Neuroradiol       Date:  2003-09       Impact factor: 3.825

2.  Intragenic Deletion in the LIFR Gene in a Long-Term Survivor with Stüve-Wiedemann Syndrome.

Authors:  Júlia Hatagami Marques; Guilherme Lopes Yamamoto; Larissa de Cássia Testai; Alexandre da Costa Pereira; Chong Ae Kim; Maria R Passos-Bueno; Débora Romeo Bertola
Journal:  Mol Syndromol       Date:  2015-05-27

3.  Case report of prenatal diagnosis of Stüve-Wiedemann Syndrome in a woman with another child affected too.

Authors:  Anita Catavorello; Salvatore Giovanni Vitale; Diego Rossetti; Lisa Caldaci; Marco Marzio Panella
Journal:  J Prenat Med       Date:  2013-07

4.  Neuropathies of Stüve-Wiedemann Syndrome due to mutations in leukemia inhibitory factor receptor (LIFR) gene.

Authors:  Alexandra E Oxford; Cheryl L Jorcyk; Julia Thom Oxford
Journal:  J Neurol Neuromedicine       Date:  2016

5.  Stüve-Wiedemann syndrome with a novel mutation in a Saudi infant.

Authors:  Jubara Alallah; Loujen Omar Alamoudi; Reham Mohmmed Makki; Aiman Shawli; Alaa T AlHarbi
Journal:  Int J Pediatr Adolesc Med       Date:  2021-10-09

Review 6.  Stüve-Wiedemann Syndrome: Update on Clinical and Genetic Aspects.

Authors:  Débora Romeo Bertola; Rachel S Honjo; Wagner A R Baratela
Journal:  Mol Syndromol       Date:  2016-03-16

7.  Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome.

Authors:  Nathalie Dagoneau; Deborah Scheffer; Céline Huber; Lihadh I Al-Gazali; Maja Di Rocco; Anne Godard; Jelena Martinovic; Annick Raas-Rothschild; Sabine Sigaudy; Sheila Unger; Sophie Nicole; Bertrand Fontaine; Jean-Luc Taupin; Jean-François Moreau; Andrea Superti-Furga; Martine Le Merrer; Jacky Bonaventure; Arnold Munnich; Laurence Legeai-Mallet; Valérie Cormier-Daire
Journal:  Am J Hum Genet       Date:  2004-01-21       Impact factor: 11.025

8.  Congenital contractures and distinctive phenotypic features consistent with Stuve-Wiedmann syndrome in a male infant.

Authors:  Ali Al Kaissi; Monika Rumpler; Robert Csepan; Franz Grill; Klaus Klaushofer
Journal:  Cases J       Date:  2008-08-21

Review 9.  Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology.

Authors:  Dawn Mikelonis; Cheryl L Jorcyk; Ken Tawara; Julia Thom Oxford
Journal:  Orphanet J Rare Dis       Date:  2014-03-12       Impact factor: 4.123

Review 10.  Clinical overview and outcome of the Stuve-Wiedemann syndrome: a systematic review.

Authors:  Hélène Warnier; Christophe Barrea; Sarah Bethlen; Isabelle Schrouff; Julie Harvengt
Journal:  Orphanet J Rare Dis       Date:  2022-04-23       Impact factor: 4.303

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.